Holen Sie sich die Stockscreener-App
39.78
0.73%
0.29
Handel nachbörslich:
39.78
Schlusskurs vom Vortag:
$39.49
Offen:
$39.43
24-Stunden-Volumen:
1.86M
Relative Volume:
0.80
Marktkapitalisierung:
$8.20B
Einnahmen:
$2.09B
Nettoeinkommen (Verlust:
$424.88M
KGV:
19.46
EPS:
2.0439
Netto-Cashflow:
$447.20M
1W Leistung:
-4.24%
1M Leistung:
-17.98%
6M Leistung:
-11.74%
1J Leistung:
-0.05%
1-Tages-Spanne:
$39.24
$40.04
1-Wochen-Bereich:
$39.24
$41.40
52-Wochen-Spanne:
$38.13
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
39.78 | 8.14B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
490.29 | 177.61B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.10 | 134.36B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
570.21 | 46.06B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.20 | 31.66B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
301.92 | 29.61B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Why is Qiagen (QGEN) down 9.4% since last earnings report? - MSN
AI in Omics Studies Market is Going to Boom | Major Giants QIAGEN, Microsoft, NVIDIA - openPR.com
JPMorgan Chase & Co. Has $33.09 Million Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience - AD HOC NEWS
Breakout Zone: Is Qiagen NV part of any major index2026 Volume & Daily Growth Stock Investment Tips - baoquankhu1.vn
Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors - MSN
Institution Moves: Is Qiagen NV stock a smart retirement pick2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
QIAGEN reports supervisory board member’s restricted stock unit vesting and share settlement - TipRanks
Agilent, Danaher could be potential buyers of Qiagenanalyst - MSN
Fundamentals Check: Does Qiagen NV align with a passive investing strategy2026 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push - AD HOC NEWS
Qiagen (NYSE:QGEN) Hits New 12-Month LowShould You Sell? - MarketBeat
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results - BioSpace
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
Qiagen N : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F) - marketscreener.com
Qiagen N.V. stock gains spotlight with new QuantiFERON-TB data amid genomics challenges - AD HOC NEWS
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention - BioSpace
Qiagen N.V. stock faces headwinds from genomics slowdown amid new TB test data - AD HOC NEWS
Deutsche Bank downgrades Qiagen NV (QGEN) - MSN
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
QGEN: New Data Highlights Efficacy of QuantiFERON-TB Gold Plus T - GuruFocus
Qiagen announces newly published data supporting efficacy of QuantiFERON - TipRanks
[IRANNOTICE] QIAGEN N.V. SEC Filing - Stock Titan
Qiagen N.V. Stock (ISIN: NL0012169213) Faces Headwinds Amid Genomics Slowdown and Strategic Shifts - AD HOC NEWS
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays - MSN
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Moors & Cabot Inc. Acquires 154,851 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. Stock (ISIN: NL0012169213) Drops 16.85% in March Amid Diagnostics Sector Headwinds - AD HOC NEWS
BlackRock Reports 10.6% Capital and 11.8% Voting Stake in Qiagen - The Globe and Mail
Qiagen N.V. Stock (ISIN: NL0012169213) Faces Pressure Amid Life Sciences Slowdown - AD HOC NEWS
Wellington Management Group LLP Lowers Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. $QGEN Position Raised by Perbak Capital Partners LLP - MarketBeat
Dnca Finance Acquires 39,063 Shares of Qiagen N.V. $QGEN - MarketBeat
Deutsche Bank upgrades Qiagen NV (QGEN) - MSN
Qiagen (NYSE:QGEN) Stock Rating Upgraded by Deutsche Bank Aktiengesellschaft - MarketBeat
Today's Analyst Upgrade: Deutsche Bank Recommends Buy for QGEN | QGEN Stock News - GuruFocus
Deutsche Bank Upgrades Qiagen NV(QGEN.US) to Buy Rating - 富途牛牛
Korea Investment CORP Sells 93,167 Shares of Qiagen N.V. $QGEN - MarketBeat
Deutsche Bank upgrades Qiagen stock rating to buy on valuation By Investing.com - Investing.com India
Deutsche Bank upgrades Qiagen stock rating to buy on valuation - Investing.com
QIAGEN NV : Upgraded to Buy by Deutsche Bank - marketscreener.com
Deutsche Bank Upgrades Qiagen NV (QGEN) to Buy - StreetInsider
Qiagen Q2 2025 Earnings Preview - MSN
Capital International Investors Boosts Holdings in Qiagen N.V. $QGEN - MarketBeat
Qiagen discloses Bank of America’s 3.05% stake following AFM notification - The Globe and Mail
Assessing Qiagen (QGEN) Valuation After Recent Share Price Weakness - Yahoo Finance
Qiagen (NYSE:QGEN) Downgraded by Zacks Research to Strong Sell - MarketBeat
Jefferies Financial Group Inc. Makes New Investment in Qiagen N.V. $QGEN - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Position in Qiagen N.V. $QGEN - MarketBeat
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
2.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):